Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

DWS Group GmbH & Co KGaA reports robust financial performance with significant net inflows and strategic initiatives, despite challenges in active equity strategies and market volatility.

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

Quarter Results/ForecastDrägerwerk AG & Co. KGaA: Dräger with strong demand in the first quarter of 2025 30.04.2025 / 07:30 CET/CESTThe issuer is solely responsible for the content of this ...

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

A German pharmaceutical company is acquiring a drug developer with operations in Research Triangle Park.

ESG/SustainabilityAsklepios Group: Publication of Asklepios CSRD Report 2024 30.04.2025 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Asklepios Group: ...

India's Adani Green Energy plans to spend 310 billion rupees ($3.64 billion) in capital expenditure to add 5 gigawatts of ...

Germany Fines Asset Manager €25 Million over Greenwashing Claims On April 2, 2025, following a three-year investigation, German prosecutors fined asset manager DWS Group GmbH & Co KgaA (DWS) €25 ...

The FDA and other HHS agencies of interest to the pharma sphere have seen President Donald Trump’s first 100 days as he ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...